Mostrar el registro sencillo del ítem

Artículo

dc.creatorStephens, Camillaes
dc.creatorRobles-Díaz, Mercedeses
dc.creatorMedina-Caliz, Inmaculadaes
dc.creatorGarcía-Cortés, Mirenes
dc.creatorRomero Gómez, Manueles
dc.creatorRodríguez Seguel, Elisa del Pilares
dc.creatorAmpuero Herrojo, Javieres
dc.creatorDelgado de la Cuesta, Juanes
dc.date.accessioned2022-10-04T16:39:03Z
dc.date.available2022-10-04T16:39:03Z
dc.date.issued2021
dc.identifier.citationStephens, C., Robles-Díaz, M., Medina-Caliz, I., García-Cortés, M., Romero Gómez, M., Rodriguez Seguel, E.D.P.,...,Delgado de la Cuesta, J. (2021). Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. Journal of hepatology, 75 (1), 86-97. https://doi.org/10.1016/j.jhep.2021.01.029.
dc.identifier.issn0168-8278es
dc.identifier.issn1600-0641es
dc.identifier.urihttps://hdl.handle.net/11441/137613
dc.description.abstractBackground & Aims Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974–0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994–0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy’s law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management.es
dc.formatapplication/pdfes
dc.format.extent13 p.es
dc.language.isoenges
dc.publisherElsevier Science BVes
dc.relation.ispartofJournal of hepatology, 75 (1), 86-97.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHepatotoxicityes
dc.subjectDILIes
dc.subjectLiver-related deathes
dc.subjectEpidemiologyes
dc.subjectCausative agentses
dc.subjectOutcomees
dc.subjectRisk factorses
dc.subjectTherapy in DILIes
dc.subjectDrug-inducees
dc.subjectAutoimmune hepatitises
dc.titleComprehensive analysis and insights gained from long-term experience of the Spanish DILI Registryes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Biología Celular
dc.relation.publisherversionhttp://doi.org/10.1016/j.jhep.2021.01.029es
dc.identifier.doi10.1016/j.jhep.2021.01.029es
dc.journaltitleJournal of hepatologyes
dc.publication.volumen75es
dc.publication.issue1es
dc.publication.initialPage86es
dc.publication.endPage97es

FicherosTamañoFormatoVerDescripción
321.pdf748.4KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional